Walleye Capital LLC Larimar Therapeutics, Inc. Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.33 - $9.89 $190,596 - $297,787	-30,110 Reduced 73.35%	10,939 $79,000
Q1 2024 May 15, 2024	SELL	$4.2 - $13.28 $73,504 - $232,413	-17,501 Reduced 29.89%	41,049 $311,000
Q4 2023 Feb 14, 2024	SELL	$2.35 - $4.71 $348,582 - $698,648	-148,333 Reduced 71.7%	58,550 $266,000
Q3 2023 Nov 14, 2023	BUY	$3.08 - $4.49 $46,674 - $68,041	15,154 Added 7.9%	206,883 $817,000
Q2 2023 Aug 14, 2023	BUY	$3.13 - $5.27 $600,111 - $1.01 Million	191,729 New	191,729 $600,000

125

66.8M

500K

61.2K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $138M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.